155 related articles for article (PubMed ID: 37631487)
1. Development of Test Programs for the Biorelevant Characterization of Esophageal-Applied Dosage Forms.
Brokmann F; Feindt F; Weitschies W; Rosenbaum C
Polymers (Basel); 2023 Aug; 15(16):. PubMed ID: 37631487
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a Dissolution Test System for the Biorelevant Characterization of Esophageal Applied Dosage Forms.
Rosenbaum CM; Brokmann F; Krause J; Weitschies W
J Pharm Sci; 2022 Jan; 111(1):62-68. PubMed ID: 34102203
[TBL] [Abstract][Full Text] [Related]
3. Polymer adhesion predictions for oral dosage forms to enhance drug administration safety. Part 3: Review of in vitro and in vivo methods used to predict esophageal adhesion and transit time.
Drumond N; Stegemann S
Colloids Surf B Biointerfaces; 2018 May; 165():303-314. PubMed ID: 29524806
[TBL] [Abstract][Full Text] [Related]
4. A novel versatile flow-donor chamber as biorelevant ex-vivo test assessing oral mucoadhesive formulations.
Gidvall S; Björklund S; Feiler A; Dahlström B; Rönn R; Engblom J; Valetti S
Eur J Pharm Sci; 2021 Nov; 166():105983. PubMed ID: 34461276
[TBL] [Abstract][Full Text] [Related]
5. Saliva transport to the distal esophagus.
Dantas RO; Oliveira RB; Aprile LR; Hara SH; Sifrim DA
Scand J Gastroenterol; 2005 Sep; 40(9):1010-6. PubMed ID: 16211700
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of Mucoadhesive-Dendrimers as Solid Dosage Forms.
Raval N; Maheshwari R; Kalia K; Tekade RK
Methods Mol Biol; 2019; 2000():93-109. PubMed ID: 31148012
[TBL] [Abstract][Full Text] [Related]
7. Development of a bio-relevant dissolution test device simulating mechanical aspects present in the fed stomach.
Koziolek M; Görke K; Neumann M; Garbacz G; Weitschies W
Eur J Pharm Sci; 2014 Jun; 57():250-6. PubMed ID: 24051217
[TBL] [Abstract][Full Text] [Related]
8. Bolus flow and biomechanical properties of the esophageal wall during primary esophageal peristalsis: Effects of bolus viscosity and posture.
Zifan A; Gandu V; Ledgerwood M; Mittal R
Neurogastroenterol Motil; 2022 Jun; 34(6):e14281. PubMed ID: 34636107
[TBL] [Abstract][Full Text] [Related]
9. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
10. Effect of bolus volume on the response of the human esophagus to a viscous bolus.
Bilder CR; Dooley CP; Valenzuela JE
Scand J Gastroenterol; 1990 May; 25(5):467-70. PubMed ID: 2359974
[TBL] [Abstract][Full Text] [Related]
11. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
Kambayashi A; Blume H; Dressman JB
Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
[TBL] [Abstract][Full Text] [Related]
12. Drug delivery from the oral cavity: a focus on mucoadhesive buccal drug delivery systems.
Shinkar DM; Dhake AS; Setty CM
PDA J Pharm Sci Technol; 2012; 66(5):466-500. PubMed ID: 23035030
[TBL] [Abstract][Full Text] [Related]
13. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
Ali J; Zgair A; Hameed GS; Garnett MC; Roberts CJ; Burley JC; Gershkovich P
Int J Pharm; 2019 Jan; 555():228-236. PubMed ID: 30465852
[TBL] [Abstract][Full Text] [Related]
14. High-resolution manometry combined with impedance measurements discriminates the cause of dysphagia in children.
Rommel N; Omari TI; Selleslagh M; Kritas S; Cock C; Rosan R; Rodriguez L; Nurko S
Eur J Pediatr; 2015 Dec; 174(12):1629-37. PubMed ID: 26105773
[TBL] [Abstract][Full Text] [Related]
15. [Mucoadhesive oral tablets--a modern dosage form with controlled drug release].
Dostálová M; Rabisková M
Ceska Slov Farm; 2000 Mar; 49(2):55-61. PubMed ID: 10953444
[TBL] [Abstract][Full Text] [Related]
16. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets.
Walsh PL; Bothe JR; Bhardwaj S; Hu M; Nofsinger R; Xia B; Persak S; Pennington J; Bak A
Drug Dev Ind Pharm; 2016; 42(5):836-44. PubMed ID: 26339722
[TBL] [Abstract][Full Text] [Related]
17. Mucoadhesive films as perspective oral dosage form.
Landová H; Daněk Z; Gajdziok J; Vetchý D; Stembírek J
Ceska Slov Farm; 2013 Feb; 62(1):4-11. PubMed ID: 23578261
[TBL] [Abstract][Full Text] [Related]
18. The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.
McCargar L; Crail D; Dansereau R; Myers W; Lane M
Int J Pharm; 2001 Jul; 222(2):191-7. PubMed ID: 11427349
[TBL] [Abstract][Full Text] [Related]
19. The challenges of drug delivery to the esophagus and how to overcome them.
Krause J; Brokmann F; Rosenbaum C; Weitschies W
Expert Opin Drug Deliv; 2022 Feb; 19(2):119-131. PubMed ID: 35062853
[TBL] [Abstract][Full Text] [Related]
20. Esophageal solid bolus transit: studies using combined multichannel intraluminal impedance and manometry in healthy volunteers.
Chen CL; Yi CH; Chou AS; Liu TT
Dis Esophagus; 2013 Jan; 26(1):91-6. PubMed ID: 22394249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
